Evolus Enterprise Value over EBIT from 2010 to 2024

EOLS Stock  USD 14.00  0.15  1.08%   
Check Evolus financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evolus main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.2 M, Interest Expense of 14.5 M or Selling General Administrative of 84.8 M, as well as many exotic indicators such as Price To Sales Ratio of 4.6, Dividend Yield of 0.0 or Operating Cycle of 197. Evolus financial statements analysis is a perfect complement when working with Evolus Valuation or Volatility modules.
  
This module can also supplement Evolus' financial leverage analysis and stock options assessment as well as various Evolus Technical models . Check out the analysis of Evolus Correlation against competitors.

About Evolus Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Evolus income statement, its balance sheet, and the statement of cash flows. Evolus investors use historical funamental indicators, such as Evolus's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although Evolus investors may use each financial statement separately, they are all related. The changes in Evolus's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Evolus's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Evolus Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Evolus. Please read more on our technical analysis and fundamental analysis pages.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 174 people.

Pair Trading with Evolus

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evolus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolus will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evolus Stock

  0.82EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Evolus Stock

  0.93VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.91MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.81CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.79KA Kineta Inc Report 29th of March 2024 PairCorr
  0.73MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Evolus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evolus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evolus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evolus Inc to buy it.
The correlation of Evolus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evolus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evolus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evolus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evolus Inc is a strong investment it is important to analyze Evolus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Evolus' future performance. For an informed investment choice regarding Evolus Stock, refer to the following important reports:
Check out the analysis of Evolus Correlation against competitors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Evolus Stock analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Revenue Per Share
3.55
Quarterly Revenue Growth
0.398
Return On Assets
(0.12)
Return On Equity
(12.79)
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.